Shuoteng's February 10 trading volume was $451 million, ranking 320th among U.S. stocks on that day.

K-LinePoet · 2026-02-11T09:12:18+00:00

On February 10, 2026, pharmaceutical company ZTS had a trading volume of $451 million, up 0.65%. Year-to-date increase is 1.84%, and the 52-week decline is 25.47%. The Q3 FY2025 financial report shows revenue increased by 2.03% year-over-year, and net profit grew by 8.09%.

K-LinePoet

2026-02-11 09:12:18

Abstract generation in progress

On February 10, 2026, Zoetis (ZTS) had a trading volume of $451 million, ranking 320th among U.S. stocks that day, with a 11.82% increase from the previous day. The trading volume was 3.5086 million shares.

Zoetis (ZTS) rose 0.65% on February 10, 2026, closing at $128.13. The stock increased by 4.67% over the past five trading days, up 2.65% for the entire month of February, and up 1.84% year-to-date. Over the past 52 weeks, it has decreased by 25.47%.

*If the company’s listing duration is less than 52 weeks, the 52-week change is calculated from the listing date to the present (this also applies to cases where the listing duration is less than one month or five trading days).

Zoetis (ZTS)	Trading Volume / USD	Change from Previous Day	Volume
February 10, 2026	$451 million	11.82%	3.5086 million
February 9, 2026	$404 million	-23.50%	3.176 million
February 6, 2026	$528 million	-10.54%	4.1277 million
February 5, 2026	$590 million	-8.78%	4.6531 million
February 4, 2026	$647 million	37.27%	5.1062 million

Zoetis released its Q3 2025 financial report (cumulative) on November 4, 2025. Revenue from January 1 to September 30, 2025, was $7.08 billion, a 2.03% increase year-over-year. Net profit was $2.07 billion, up 8.09% year-over-year.

Zoetis was founded in July 2012 in Delaware, USA. It is a global leader in the animal health industry, focusing on the discovery, development, manufacturing, and commercialization of drugs, vaccines, diagnostic products and services, biological devices, gene testing, and precision animal health.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.